Biological therapy dramatically changed the management of Ulcerative Colitis (UC). However, a significant number of these patients fail to respond or have secondary loss of response to this strategy. In this clinical situation, the options include intensification of anti-TNF therapy, the use of a second anti-TNF or being switched to another drug class. Among the later, tofacitinib, an oral small molecule directed against the JAK/STAT pathway, is safe and effective in inducing and maintaining remission in patients with moderate-severe UC. We report two patients with UC refractory to conventional treatment and biological therapy, who responded successfully to the use of tofacitinib.
|Translated title of the contribution||Tofacitinib for the treatment of ulcerative colitis. Report of two cases|
|Number of pages||5|
|Journal||Revista Medica de Chile|
|State||Published - Jul 2020|
Bibliographical notePublisher Copyright:
© 2020 Sociedad Medica de Santiago. All rights reserved.
- Inflammatory Bowel Diseases
- Janus Kinases
- Ulcerative colitis